Furthermore, an anti‐IL‐8 drug (BMS‐986253) is under testing for COVID‐19 patients in a Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT04347226). This evidence concerns the gene CXCL8 and COVID-19.